Filibuvir
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 319827

CAS#: 877130-28-4

Description: Filibuvir, also known as PF00868554, is a non-nucleoside orally available NS5B inhibitor under development for the treatment of hepatitis C. It binds to the non-catalytic Thumb II allosteric pocket of NS5B viral polymerase and causes a decrease in viral RNA synthesis. It is a potent and selective inhibitor, with a mean IC50 of 0.019 μM against genotype 1 polymerases. Its investigation was discontinued on February 2013 due to strategic reasons.

Chemical Structure

img
Filibuvir
CAS# 877130-28-4
Instruction

Theoretical Analysis

MedKoo Cat#: 319827
Name: Filibuvir
CAS#: 877130-28-4
Chemical Formula: C29H37N5O3
Exact Mass: 503.29
Molecular Weight: 503.647
Elemental Analysis: C, 69.16; H, 7.41; N, 13.91; O, 9.53

Price and Availability

Size Price Availability Quantity
5mg USD 265 2 Weeks
25mg USD 715 2 Weeks
Bulk inquiry

Synonym: PF00868554; PF-00868554; P 00868554; PF868554; PF-868554; PF 868554; Filibuvir

IUPAC/Chemical Name: (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydro-2H-pyran-2-one

InChi Key: SLVAPEZTBDBAPI-GDLZYMKVSA-N

InChi Code: InChI=1S/C29H37N5O3/c1-5-22-14-20(15-23(6-2)31-22)11-12-29(21-9-7-8-10-21)17-25(35)24(27(36)37-29)16-26-32-28-30-18(3)13-19(4)34(28)33-26/h13-15,21,35H,5-12,16-17H2,1-4H3/t29-/m1/s1

SMILES Code: O=C1C(CC2=NN3C(C)=CC(C)=NC3=N2)=C(O)C[C@](CCC4=CC(CC)=NC(CC)=C4)(C5CCCC5)O1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 503.65 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Beaulieu PL. Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection. IDrugs. 2010 Dec;13(12):938-48. PMID: 21154154.


2: Rodriguez-Torres M, Yoshida EM, Marcellin P, Srinivasan S, Purohit VS, Wang C, Hammond JL. A phase 2 study of filibuvir in combination with pegylated IFN alfa and ribavirin for chronic HCV. Ann Hepatol. 2014 Jul-Aug;13(4):364-75. PMID: 24927607.


3: Wagner F, Thompson R, Kantaridis C, Simpson P, Troke PJ, Jagannatha S, Neelakantan S, Purohit VS, Hammond JL. Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients. Hepatology. 2011 Jul;54(1):50-9. doi: 10.1002/hep.24342. PMID: 21488067.


4: Troke PJ, Lewis M, Simpson P, Gore K, Hammond J, Craig C, Westby M. Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus-infected patients. Antimicrob Agents Chemother. 2012 Mar;56(3):1331-41. doi: 10.1128/AAC.05611-11. Epub 2011 Dec 27. PMID: 22203605; PMCID: PMC3294886.


5: Wang H, Guo C, Chen BZ, Ji M. Computational study on the drug resistance mechanism of HCV NS5B RNA-dependent RNA polymerase mutants V494I, V494A, M426A, and M423T to Filibuvir. Antiviral Res. 2015 Jan;113:79-92. doi: 10.1016/j.antiviral.2014.11.005. Epub 2014 Nov 15. PMID: 25449363.


6: Yi G, Deval J, Fan B, Cai H, Soulard C, Ranjith-Kumar CT, Smith DB, Blatt L, Beigelman L, Kao CC. Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir. Antimicrob Agents Chemother. 2012 Feb;56(2):830-7. doi: 10.1128/AAC.05438-11. Epub 2011 Dec 5. PMID: 22143520; PMCID: PMC3264230.


7: Strohmeyer HE, Sluggett GW. Determination and control of TEMPO, a potentially genotoxic free radical reagent used in the synthesis of filibuvir. J Pharm Biomed Anal. 2012 Mar 25;62:216-9. doi: 10.1016/j.jpba.2011.12.036. Epub 2012 Jan 8. PMID: 22269174.


8: Hooda P, Al-Dosari M, Sinha N, Parvez MK, Sehgal D. Inhibition of HEV Replication by FDA-Approved RdRp Inhibitors. ACS Omega. 2023 Oct 27;8(44):41570-41578. doi: 10.1021/acsomega.3c05637. PMID: 37969986; PMCID: PMC10633873.


9: Winquist J, Abdurakhmanov E, Baraznenok V, Henderson I, Vrang L, Danielson UH. Resolution of the interaction mechanisms and characteristics of non- nucleoside inhibitors of hepatitis C virus polymerase. Antiviral Res. 2013 Mar;97(3):356-68. doi: 10.1016/j.antiviral.2012.12.027. Epub 2013 Jan 7. PMID: 23305851.


10: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Dec;31(10):661-700. PMID: 20140276.


11: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010 Nov;32(9):675-703. doi: 10.1358/mf.2010.32.9.1563109. PMID: 21225019.


12: Abdurakhmanov E, Øie Solbak S, Danielson UH. Biophysical Mode-of-Action and Selectivity Analysis of Allosteric Inhibitors of Hepatitis C Virus (HCV) Polymerase. Viruses. 2017 Jun 16;9(6):151. doi: 10.3390/v9060151. PMID: 28621755; PMCID: PMC5490826.


13: Ruan Z, Liu C, Guo Y, He Z, Huang X, Jia X, Yang T. SARS-CoV-2 and SARS-CoV: Virtual screening of potential inhibitors targeting RNA-dependent RNA polymerase activity (NSP12). J Med Virol. 2021 Jan;93(1):389-400. doi: 10.1002/jmv.26222. Epub 2020 Jul 9. PMID: 32579254; PMCID: PMC7361265.


14: Bessa LM, Launay H, Dujardin M, Cantrelle FX, Lippens G, Landrieu I, Schneider R, Hanoulle X. NMR reveals the intrinsically disordered domain 2 of NS5A protein as an allosteric regulator of the hepatitis C virus RNA polymerase NS5B. J Biol Chem. 2017 Nov 3;292(44):18024-18043. doi: 10.1074/jbc.M117.813766. Epub 2017 Sep 14. PMID: 28912275; PMCID: PMC5672029.


15: Fernández-Montero JV, Soriano V. Perspectivas futuras en el tratamiento de la hepatitis crónica C [Future perspective in the treatment of chronic hepatitis C]. Rev Esp Sanid Penit. 2011;13(1):21-9. Spanish. doi: 10.4321/s1575-06202011000100004. PMID: 21484075.


16: Eltahla AA, Tay E, Douglas MW, White PA. Cross-genotypic examination of hepatitis C virus polymerase inhibitors reveals a novel mechanism of action for thumb binders. Antimicrob Agents Chemother. 2014 Dec;58(12):7215-24. doi: 10.1128/AAC.03699-14. Epub 2014 Sep 22. PMID: 25246395; PMCID: PMC4249545.


17: Solbak SMØ, Abdurakhmanov E, Vedeler A, Danielson UH. Characterization of interactions between hepatitis C virus NS5B polymerase, annexin A2 and RNA - effects on NS5B catalysis and allosteric inhibition. Virol J. 2017 Dec 11;14(1):236. doi: 10.1186/s12985-017-0904-4. PMID: 29228983; PMCID: PMC5725786.


18: Graham EJ, Hunt R, Shaw SM, Pickford C, Hammond J, Westby M, Targett-Adams P. Colony-forming assays reveal enhanced suppression of hepatitis C virus replication using combinations of direct-acting antivirals. J Virol Methods. 2011 Jun;174(1-2):153-7. doi: 10.1016/j.jviromet.2011.03.031. Epub 2011 Apr 5. PMID: 21473883.


19: Gentile I, Buonomo AR, Zappulo E, Borgia G. Discontinued drugs in 2012 - 2013: hepatitis C virus infection. Expert Opin Investig Drugs. 2015 Feb;24(2):239-51. doi: 10.1517/13543784.2015.982274. Epub 2014 Nov 11. PMID: 25384989.


20: Fenaux M, Eng S, Leavitt SA, Lee YJ, Mabery EM, Tian Y, Byun D, Canales E, Clarke MO, Doerffler E, Lazerwith SE, Lew W, Liu Q, Mertzman M, Morganelli P, Xu L, Ye H, Zhang J, Matles M, Murray BP, Mwangi J, Zhang J, Hashash A, Krawczyk SH, Bidgood AM, Appleby TC, Watkins WJ. Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother. 2013 Feb;57(2):804-10. doi: 10.1128/AAC.02052-12. Epub 2012 Nov 26. PMID: 23183437; PMCID: PMC3553741.